Linvoseltamab bla for treatment of relapsed/refractory multiple myeloma accepted for fda priority review

Tarrytown, n.y., feb. 21, 2024 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has accepted for priority review the biologics license application (bla) for linvoseltamab to treat adult patients with relapsed/refractory (r/r) multiple myeloma (mm) that has progressed after at least three prior therapies. the target action date for the fda decision is august 22, 2024. linvoseltamab is an investigational bispecific antibody designed to bridge b-cell maturation antigen on multiple myeloma cells with cd3-expressing t cells to facilitate t-cell activation and cancer-cell killing.
REGN Ratings Summary
REGN Quant Ranking